UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1057-14
Program Prior Authorization/Notification
Medication Javygtor™ (sapropterin dihydrochloride)*, Kuvan® (sapropterin
dihydrochloride)*
P&T Approval Date 4/2008, 4/2009, 3/2010, 3/2011, 1/2012, 2/2013, 10/2013, 10/2014,
10/2015, 9/2016, 9/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022,
3/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Javygtor and Kuvan are phenylalanine hydroxylase activators indicated to reduce blood
phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with
hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria
(PKU). Javygtor and Kuvan are to be used in conjunction with a Phe-restricted diet.
2. Coverage Criteriaa:
A. Initial Authorization
1. Javygtor* and Kuvan* will be approved based on all of the following criteria:
a. Diagnosis of phenylketonuria (PKU)
-AND-
b. Patient is actively on a Phe-restricted diet
-AND-
c. Patient is not receiving the requested medication in combination with Palynziq
(pegvaliase-pqpz)
Authorization will be issued for 12 months.
B. Reauthorization
1. Javygtor* and Kuvan* will be approved based on all of the following criteria:
a. Patient is actively on a Phe-restricted diet
-AND-
b. Blood Phe levels continue to remain lower than baseline level
-AND-
© 2025 UnitedHealthcare Services Inc.
1
c. Patient is not receiving the requested medication in combination with Palynziq
(pegvaliase-pqpz)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Javygtor and Brand Kuvan are typically excluded from coverage. Tried/Failed criteria may be in
place. Please refer to plan specifics to determine exclusion status.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may also be in place.
4. References:
1. Kuvan [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; August 2024.
2. Javygtor [package insert]. Princeton, NJ: Dr. Reddy’s Laboratories, Inc.; October 2024.
3. Javygtor powder for oral solution [package insert]. Princeton, NJ: Dr. Reddy’s Laboratories,
Inc.; October 2024.
4. Smith WE, Berry SA, Bloom K, et al. Phenylalanine hydroxylase deficiency diagnosis and
management: A 2023 evidence-based clinical guideline of the American College of Medical
Genetics and Genomics (ACMG). Genet Med. 2025;27(1):101289.
doi:10.1016/j.gim.2024.101289
Program Prior Authorization/Notification – Javygtor and Kuvan (sapropterin
dihydrochloride)
Change Control
10/2013 Removed age criterion.
10/2014 Annual review. Updated references.
10/2015 Annual review. Updated authorization period to 6 mo. Updated
reauthorization requirement. Background edit. Updated references.
9/2016 Annual review. Updated references.
9/2017 Annual review with no changes to coverage criteria.
7/2018 Added criteria restricting combination use with Palynziq
12/2018 Administrative change to add statement regarding use of automated
processes.
7/2019 Annual review with no changes to coverage criteria. Updated reference.
7/2020 Annual review with no changes to coverage criteria. Updated reference.
7/2021 Annual review with no changes to clinical criteria. Updated re-
authorization to 12 months. Added statement that Brand Kuvan is
excluded from coverage for the majority of our benefits. Updated
background and references.
© 2025 UnitedHealthcare Services Inc.
2
7/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote.
3/2023 Added Javygtor to program. Updated exclusion footnote and
references.
3/2024 Annual review. Updated authorization approval duration to 12 months.
Updated reference.
3/2025 Annual review. Updated references.
© 2025 UnitedHealthcare Services Inc.
3